Higher revenue and lower profit in the biopsy equipment segment
First written in FY2019-Q1. 4 of 29 entries say "Restated". Latest entry: 2026-07-31.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「Sales of electrocardiograph-related products, automated hematology analyzers, blood pressure and pulse wave testing systems, and other products declined, bringing consolidated net sales to ¥1,107.0 million, down 6.9% year on year, and operating profit to ¥154.2 million, down 12.4%.」
The biological testing equipment segment continued to post lower sales and earnings due to declining product sales. - FY2025Lower revenue and profit continuedAnnual report
「Sales of ultrasound diagnostic imaging systems, blood pressure and pulse wave testing systems, and locally sourced products declined, bringing consolidated net sales to ¥2,854.9 million, down 6.9% year on year, and segment profit to ¥478.2 million, down 5.8%.」
The Biosignal Testing Equipment segment shifted from lower sales and higher profit in the previous fiscal year to lower sales and lower profit in the current fiscal year. - FY2025-H1Shift to lower revenue and profitAnnual report
「Sales of electrocardiograph-related products, ultrasound diagnostic imaging systems, blood pressure and pulse wave testing systems, and other products declined, bringing consolidated net sales to ¥1,188.8 million, down 8.7% year on year, and operating profit to ¥176.1 million, down 26.1%.」
The Biosignal Testing Equipment segment shifted from lower sales and higher profit in FY2024 to lower sales and lower operating profit in the current interim consolidated fiscal period. - FY2024Continued revenue decline and profit growthAnnual report
「Sales of blood pressure and pulse wave testing systems and automated hematology analyzers declined, bringing consolidated net sales to ¥3,066.4 million, down 1.3% year on year, while segment profit rose to ¥507.4 million, up 3.7%.」
The Biosignal Testing Equipment segment posted lower sales due to declines in blood pressure and pulse wave testing systems and automated hematology analyzers, while segment profit increased. - FY2024-Q3Lower sales, continued profit growth, and narrower profit growthAnnual report
「Sales of blood pressure and pulse wave testing systems and automated hematology analyzers declined, bringing consolidated net sales to ¥1,951.5 million, down 2.3% year on year, while operating profit rose to ¥334.4 million, up 11.5%.」
The Biosignal Testing Equipment segment continued to post lower sales but higher operating profit. Year on year, the rate of operating profit growth narrowed from 15.7% in the cumulative previous quarter to 11.5%. - FY2024-Q2Shift to revenue decline and earnings growthAnnual report
「Sales of blood pressure and pulse wave testing systems and automated hematology analyzers declined, bringing consolidated net sales to ¥1,302.6 million, down 2.9% year on year, while operating profit rose to ¥238.2 million, up 15.7%.」
The Biosignal Testing Equipment segment shifted from higher sales and lower profit in the first quarter to lower sales but higher operating profit, as sales of blood pressure and pulse wave testing systems and automated hematology analyzers declined. - FY2024-Q1Revenue and Profit Growth ContinuesAnnual report
「Sales of automated hematology analyzers increased, bringing consolidated net sales to ¥512.1 million, up 0.9% year on year, and operating profit to ¥75.4 million, up 29.2%.」
The Biosignal Testing Equipment segment posted higher sales due to increased sales of automated hematology analyzers, and operating profit also increased. - FY2023AdvancedAnnual report
「Sales of electrocardiograph-related products, blood pressure and pulse wave testing systems, and automated hematology analyzers increased, bringing consolidated net sales to ¥3,105.8 million, up 5.6% year on year, and segment profit to ¥489.1 million, up 18.4%.」
The Biosignal Testing Equipment segment posted higher full-year sales and profit, driven by growth in electrocardiograph-related products, blood pressure and pulse wave testing systems, and automated hematology analyzers. - FY2023-Q3Continued revenue and profit growth, slower growth ratesAnnual report
「Sales of electrocardiograph-related products, blood pressure and pulse wave testing systems, and automated hematology analyzers increased, bringing consolidated net sales to ¥1,997.3 million, up 6.0% year on year, and operating profit to ¥300.0 million, up 18.4%.」
The Biosignal Testing Equipment segment continued to post higher sales and higher profit, but growth slowed from the 9.4% increase in sales and 28.7% increase in operating profit in FY2023-Q2. - FY2023-Q2Shift to higher sales and profitAnnual report
「Sales of electrocardiograph-related products, blood pressure and pulse wave testing systems, and automated hematology analyzers increased, bringing consolidated net sales to ¥1,341.7 million, up 9.4% year on year, and operating profit to ¥205.9 million, up 28.7%.」
Following higher sales but lower profit in the first quarter, the segment shifted to higher sales and higher profit as sales of electrocardiograph-related products, blood pressure and pulse wave testing systems, and automated hematology analyzers increased. - FY2023-Q1Continued revenue growth and profit declineAnnual report
「Sales of blood pressure and pulse wave testing systems increased, bringing consolidated net sales to ¥507.5 million, up 1.2% year on year, and operating profit to ¥58.3 million, down 2.3%.」
The Biosignal Testing Equipment segment posted higher sales due to increased sales of blood pressure and pulse wave testing systems, while operating profit declined. - FY2022Higher profit; fewer large-scale business negotiationsAnnual report
「Sales of electrocardiograph-related products increased, but large-scale business negotiations declined. Consolidated sales were ¥29,422 million, and segment profit was ¥4,129 million, up 25.1% year on year.」
In the biospecimen testing equipment segment, the increase in sales of electrocardiograph-related products and the decline in large-scale business negotiations are both noted, while segment profit increased. - FY2022-Q3RestatedAnnual report
「Sales of electrocardiograph-related products increased, but large-scale business negotiations declined. Consolidated sales were ¥18,849 million, and operating profit was ¥2,533 million, up 34.8% year on year.」
In the biospecimen testing equipment segment, the increase in sales of electrocardiograph-related products and the decline in large-scale business negotiations are both noted, while operating profit increased 34.8% year on year. - FY2022-Q2Higher profit; fewer large-scale business negotiations continueAnnual report
「Sales of electrocardiograph-related products increased, but large-scale business negotiations declined. Consolidated sales were ¥12,268 million, and operating profit was ¥1,600 million, up 53.6% year on year.」
The increase in sales of electrocardiograph-related products and the decline in large-scale business negotiations are both noted. The year-on-year change in sales is not stated, while operating profit increased. - FY2022-Q1Higher profit; fewer large-scale business negotiationsAnnual report
「Sales of electrocardiograph-related products increased, but large-scale business negotiations declined. Consolidated sales were ¥5,013 million, and operating profit was ¥597 million, up 133.9% year on year.」
The increase in sales of electrocardiograph-related products and the decline in large-scale business negotiations are both noted. The year-on-year change in sales is not stated due to the application of the accounting standards, while operating profit increased. - FY2021AdvancedAnnual report
「An increase in large-scale business negotiations resulted in consolidated sales of ¥40,445 million, up 5.8% year on year, and segment profit of ¥3,301 million, up 30.5%.」
The biospecimen testing equipment segment shifted from lower revenue and higher profit in the previous fiscal year to higher revenue and higher profit for the full fiscal year, with growth in large-scale business negotiations boosting performance. - FY2021-Q3Higher revenue and higher profit continue, but growth slowsAnnual report
「Although sales of electrocardiograph-related products and IT-related products declined, large-scale business negotiations increased, resulting in consolidated sales of ¥26,738 million, up 3.9% year on year, and operating profit of ¥1,878 million, up 17.0%.」
The biospecimen testing equipment segment maintained higher revenue and higher profit due to an increase in large-scale business negotiations, but the growth rates of sales and operating profit slowed compared with the previous cumulative quarter. - FY2021-Q2Lower revenue and profit continuedAnnual report
「Sales of electrocardiograph-related products and IT-related products declined, resulting in consolidated sales of ¥15,728 million, down 17.8% year on year, and operating profit of ¥1,041 million, down 21.1%.」
The biospecimen testing equipment segment continued to report lower revenue and lower profit following the first quarter. The company disclosed declines in sales of electrocardiograph-related products and IT-related products. - FY2021-Q1Shift from revenue growth and earnings decline to declines in bothAnnual report
「Sales of electrocardiograph-related products and IT-related products declined, resulting in consolidated sales of ¥6,259 million, down 9.2% year on year, and operating profit of ¥255 million, down 30.1%.」
The segment shifted from higher revenue and lower profit in the first quarter of the previous fiscal year to lower revenue and lower profit, accompanied by declines in sales of electrocardiograph-related products and IT-related products. - FY2020Shifted to lower full-year revenue and profitsAnnual report
「Sales of electrocardiograph-related products and automated hematology analyzers declined, resulting in consolidated sales of ¥38,234 million, down 1.7% year on year, and segment profit of ¥2,530 million, down 5.7%.」
The biospecimen testing equipment segment shifted from lower revenue and higher profit in the previous fiscal year to lower revenue and lower segment profit in the current fiscal year. - FY2020-Q3Continued revenue and profit growth, slower growth ratesAnnual report
「Growth in large-scale business negotiations and IT-related products drove consolidated sales to ¥25,730 million, up 6.0% year on year, and operating profit to ¥1,605 million, up 2.7%.」
The biospecimen testing equipment segment maintained higher revenue and higher profit on growth in large-scale business negotiations and IT-related products, but the growth rates of sales and operating profit slowed compared with the previous cumulative quarter. - FY2020-Q2Turnaround from revenue and profit declines to revenue and profit growthAnnual report
「Growth in large-scale business negotiations and IT-related products drove consolidated sales to ¥19,127 million, up 22.0% year on year, and operating profit to ¥1,319 million, up 24.5%.」
The segment shifted from lower revenue and lower profit in the same period of the previous year to higher revenue and higher profit in the first six months of the current fiscal year, driven by growth in large-scale business negotiations and IT-related products. - FY2020-Q1RestatedAnnual report
「Although sales of electrocardiograph-related products and automated hematology analyzers declined, sales increased on growth in large-scale business negotiations. Consolidated sales were ¥6,892 million, up 3.8% year on year, and operating profit was ¥365 million, down 8.5%.」
The biospecimen testing equipment segment reconfirmed the same performance mix as in the same period of the previous year, with higher revenue and lower profit. Growth in large-scale business negotiations offset declines in sales of electrocardiograph-related products and other products. - FY2019Shift from higher revenue and lower profit to lower revenue and higher profitAnnual report
「In the biospecimen testing equipment segment, sales of electrocardiograph-related products increased, but consolidated sales declined to ¥38,912 million, down 0.9% year on year, due to fewer large-scale business negotiations, while segment profit increased 7.2% to ¥2,684 million.」
The segment shifted from higher revenue and lower profit in the previous fiscal year to lower revenue but higher segment profit in the current fiscal year. - FY2019-Q3Revenue shifted from decline to growth; earnings decline continuedAnnual report
「Sales of electrocardiograph-related products increased. As a result, the biospecimen testing equipment segment reported sales of ¥24,274 million for the first nine months of the current consolidated fiscal year, up 1.9% year on year, and operating profit of ¥1,562 million, down 2.9%.」
The segment shifted from lower revenue and lower profit for the first six months to higher revenue and lower profit for the first nine months of the current fiscal year. - FY2019-Q2Shift from higher revenue to lower revenue; lower profit continuesAnnual report
「As a result, the biospecimen testing equipment segment reported sales of ¥15,677 million for the first six months of the current consolidated fiscal year, down 4.8% year on year, and operating profit of ¥1,059 million, down 7.7%.」
The segment shifted from higher revenue and lower profit in the first quarter to lower revenue and lower profit for the first six months of the current fiscal year. - FY2019-Q1First statedAnnual report
「As a result, the biospecimen testing equipment segment reported sales of ¥6,639 million for the first quarter of the current consolidated fiscal year, up 2.8% year on year, and operating profit of ¥399 million, down 7.7%.」
The company has recorded for the first time that, although sales of electrocardiograph-related products and automated hematology analyzers increased in the biospecimen testing equipment segment, segment operating profit declined year on year.